论文部分内容阅读
目的:探讨阿德福韦酯(ADV)单用或联合拉米夫定治疗YMDD变异的活动型肝炎肝硬化的疗效及安全性。方法:112例研究对象按1∶1比例随机分为两组。联合组:继续接受拉米夫定100 mg/d口服治疗,全程联合ADV 10mg/d口服;单用组:拉米夫定100 mg/d和ADV 10 mg/d联合治疗2个月后单用ADV 10 mg/d口服。疗程1 a。结果:治疗1 a时,联合组肝功及Child-Pugh评分改善优于单用组(P<0.01),HBV-DNA阴转率显著高于单用组(P<0.05)。结论:阿德福韦酯联合拉米夫定治疗YMDD变异的活动型肝炎肝硬化患者在病毒学及生化学方面优于单用阿德福韦酯,两组安全性均良好。
Objective: To investigate the efficacy and safety of adefovir dipivoxil (ADV) alone or in combination with lamivudine in the treatment of active cirrhosis with YMDD mutation. Methods: One hundred and twelve subjects were randomly divided into two groups according to the ratio of 1: 1. Combination group: continue to receive lamivudine 100 mg / d oral treatment, combined with ADV 10mg / d orally; single use group: lamivudine 100 mg / d and ADV 10 mg / d combination therapy for 2 months after the single use ADV 10 mg / d orally. Treatment 1 a. Results: At 1 year, the liver function and Child-Pugh scores in the combined group were better than those in the single group (P <0.01), and the negative rates of HBV DNA in the combined group were significantly higher than those in the single group (P <0.05). CONCLUSION: Adefovir dipivoxil and lamivudine are superior to adefovir dipivoxil alone in the treatment of active hepatitis cirrhosis due to YMDD mutation in both virology and biochemistry. The safety of both groups is good.